| B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial 2010 · B vitamins · Patients with recent stroke or transient ischaemic attack within the past 7 months | 25 mg | 2 mg | 1241 days | 4,089 |
| Treatment with B vitamins and incidence of cancer in patients with previous stroke or transient ischemic attack: results of a randomized placebo-controlled trial 2012 · B vitamins · Patients with recent stroke or transient ischemic attack | 25 mg | 2 mg | 1241 days | 4,082 |
| Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial 2012 · B-vitamins group · Adults with a stroke or transient ischaemic attack within the previous 7 months; men and women, age not restricted | 25 mg | 2 mg | 1241 days | 4,040 |
| Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial 2008 · Active treatment · Women aged 40 years or older with a history of cardiovascular disease or at least three cardiovascular risk factors | 50 mg | 2.5 mg | 2665 days | 2,721 |
| Folic acid, pyridoxine, and cyanocobalamin combination treatment and age-related macular degeneration in women: the Women's Antioxidant and Folic Acid Cardiovascular Study 2009 · folic acid/B6/B12 group · Women at high risk of cardiovascular disease, with preexisting cardiovascular disease or at least three coronary risk factors; women included in these AMD analyses had no AMD diagnosis at baseline. | 50 mg | 2.5 mg | 2665 days | 2,607 |
| Effect of homocysteine-lowering treatment with folic Acid and B vitamins on risk of type 2 diabetes in women: a randomized, controlled trial 2009 · Active treatment · Women aged 45 years or older at high risk for cardiovascular disease, without diabetes at baseline | 50 mg | 2.5 mg | 2665 days | 2,132 |
| Folic Acid, Vitamin B6, and Vitamin B12 in Combination and Age-Related Cataract in a Randomized Trial of Women 2016 · combination treatment group · Women with preexisting cardiovascular disease or at least three coronary risk factors; ages 40 and older | 50 mg | 2.5 mg | 2665 days | 1,969 |
| B vitamins to enhance treatment response to antidepressants in middle-aged and older adults: results from the B-VITAGE randomised, double-blind, placebo-controlled trial 2014 · vitamins · Community-dwelling adults aged 50 years or over with DSM-IV-TR major depression | 25 mg | 2 mg | 52 weeks | 77 |
| Homocysteine lowering with folic acid and B vitamins in vascular disease 2006 · active-treatment group · Patients aged 55 years or older with vascular disease or diabetes | 50 mg | 2.5 mg | 5 years | — |
| Effect of combined folic acid, vitamin B6, and vitamin B12 on cancer risk in women: a randomized trial 2008 · combined folic acid/vitamin B6/vitamin B12 treatment · Women aged 40 years or older with a history of cardiovascular disease or at least three coronary risk factors | 50 mg | 2.5 mg | 2666 days | — |
| Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial 2009 · vitamin therapy group · Adults with known cardiovascular disease | 50 mg | 2.5 mg | 5 years | — |
| B-vitamins reduce the long-term risk of depression after stroke: The VITATOPS-DEP trial 2010 · B-vitamins · Stroke survivors; age and sex not specified | 25 mg | 2 mg | 383 days | — |
| Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial 2008 · folic acid plus vitamin B12 plus vitamin B6 · Adults undergoing coronary angiography with coronary artery disease or aortic valve stenosis | 40 mg | 800 mcg | 165 weeks | 772 |
| Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial 2002 · homocysteine-lowering therapy · Patients with coronary artery disease after successful percutaneous coronary intervention; age and sex not specified | 10 mg | 1 mg | 26 weeks | 272 |
| Effectiveness of homocysteine lowering vitamins in prevention of thrombotic tendency at high altitude area: A randomized field trial 2015 · intervention · Indian soldiers freshly inducted to a high-altitude area | 3 mg | 5 mg | 2 years | — |
| Effect of B vitamins and lowering homocysteine on cognitive impairment in patients with previous stroke or transient ischemic attack: a prespecified secondary analysis of a randomized, placebo-controlled trial and meta-analysis 2013 · B-vitamins · Patients with previous stroke or transient ischemic attack who were cognitively unimpaired at the cognitive assessment | 25 mg | 2 mg | 1241 days | 1,110 |
| A trial of B vitamins and cognitive function among women at high risk of cardiovascular disease 2008 · B vitamin group · Women aged 65 years or older with cardiovascular disease or at least three coronary risk factors; female health professionals | 50 mg | 2.5 mg | 2411 days | — |
| Effects of maternal micronutrient supplementation on fetal loss and infant mortality: a cluster-randomized trial in Nepal 2003 · Multiple micronutrients · Pregnant women in rural Nepal | 2.2 mg | 400 mcg | — | — |
| Multivitamin supplementation of HIV-positive women during pregnancy reduces hypertension 2005 · Multivitamin plus vitamin A · HIV-positive pregnant Tanzanian women | 25 mg | 800 mcg | — | — |
| Multivitamin supplementation of HIV-positive women during pregnancy reduces hypertension 2005 · Multivitamin without vitamin A · HIV-positive pregnant Tanzanian women | 25 mg | 800 mcg | — | — |
| Aged garlic extract with supplement is associated with increase in brown adipose, decrease in white adipose tissue and predict lack of progression in coronary atherosclerosis 2013 · AGE-S · Subjects evaluated for coronary artery calcium; age, sex, and specific condition are not stated | 12.5 mg | 300 mcg | 1 year | — |
| Homocysteine lowering and cognition in CKD: the Veterans Affairs homocysteine study 2009 · vitamin group · Adults aged 21 years or older with advanced chronic kidney disease or end-stage renal disease and high plasma homocysteine | 100 mg | 40 mg | 1128 days | 339 |
| High-dose B vitamin supplementation and progression of subclinical atherosclerosis: a randomized controlled trial 2009 · B-vitamin group · Men and postmenopausal women aged 40 years or older with fasting total homocysteine ≥8.5 μmol/L and no clinical signs or symptoms of cardiovascular disease | 50 mg | 5 mg | 1132 days | 254 |
| High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial 2008 · high-dose supplement group · Adults over 50 with mild to moderate probable Alzheimer disease and normal vitamin B12 and folate levels | 25 mg | 5 mg | 548 days | 240 |
| Vitamins B12, B6, and folic acid for onset of depressive symptoms in older men: results from a 2-year placebo-controlled randomized trial 2008 · treatment with vitamins · Men aged 75 years and older, free of clinically significant depression at baseline | 25 mg | 2 mg | 2 years | 150 |
| Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial 2012 · B-vitamin group · Adults aged 70 years or older with mild cognitive impairment | 20 mg | 800 mcg | 2 years | 133 |
| Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial 2010 · Active treatment group · Adults aged 70 years or older with mild cognitive impairment | 20 mg | 800 mcg | 2 years | 85 |
| Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial 2000 · treatment group · Healthy siblings of patients with premature atherothrombotic disease | 250 mg | 5 mg | 2 years | 78 |
| Additive effect of homocysteine- and cholesterol-lowering therapy on endothelium-dependent vasodilation in patients with cardiovascular disease 2012 · combined therapy · Patients with cardiovascular disease at high cardiovascular risk; age and sex not reported | 10 mg | 1 mg | 6 weeks | 36 |
| Additive effect of homocysteine- and cholesterol-lowering therapy on endothelium-dependent vasodilation in patients with cardiovascular disease 2012 · group V · Patients with cardiovascular disease at high cardiovascular risk; age and sex not reported | 10 mg | 1 mg | 6 weeks | 18 |
| Short-Term Effects of Folate Supplementation in Combination With Vitamin B6 for Treating Acute Manic Episodes in Bipolar I Disorder: A Randomized Controlled Trial 2025 · Folate/vitamin B6 group · Adults aged 18–45 with bipolar I disorder in an acute manic episode | 80 mg | 5 mg | 6 weeks | 14 |
| Significant correlations of plasma homocysteine and serum methylmalonic acid with movement and cognitive performance in elderly subjects but no improvement from short-term vitamin therapy: a placebo-controlled randomized study 2005 · Vitamin therapy · Community-dwelling elderly adults, median age 76 years; both sexes; vitamin deficiencies were present in a subset | 3 mg | 800 mcg | 120 days | — |
| Folate and vitamin B6 rapidly normalize endothelial dysfunction in children with type 1 diabetes mellitus 2006 · Folate/vitamin B6 · Children with type 1 diabetes mellitus; age and sex not specified | 100 mg | 5 mg | 8 weeks | — |
| Clinical trial: B vitamins improve health in patients with coeliac disease living on a gluten-free diet 2009 · B vitamin supplementation · Adults aged 45–64 years with longstanding coeliac disease, on a strict gluten-free diet for several years | 3 mg | 800 mcg | 26 weeks | — |
| Coronary blood flow in patients with stable coronary artery disease treated long term with folic acid and vitamin B12 2011 · Folic acid and vitamin B12 plus vitamin B6 · Adults with stable coronary artery disease; mean age 57.8 years; sex not specified | 40 mg | 800 mcg | 2 years | — |
| The effects of folic acid and pyridoxine supplementation on characteristics of migraine attacks in migraine patients with aura: A double-blind, randomized placebo-controlled, clinical trial 2017 · folic acid plus pyridoxine · Adults aged 18–65 with migraine with aura | 80 mg | 5 mg | 90 days | — |
| B-Vitamin Therapy for Kidney Transplant Recipients Lowers Homocysteine and Improves Selective Cognitive Outcomes in the Randomized FAVORIT Ancillary Cognitive Trial 2017 · treatment group (high-dose vitamin group) · Men and women aged 35–75 with stable kidney function for at least 6 months after kidney transplantation and elevated plasma homocysteine | 50 mg | 5 mg | 2008 days | — |
| The Vitamins in Psychosis Study: A Randomized, Double-Blind, Placebo-Controlled Trial of the Effects of Vitamins B(12), B(6), and Folic Acid on Symptoms and Neurocognition in First-Episode Psychosis 2019 · B-vitamin supplement group · Patients with first-episode psychosis; age and sex not specified | 50 mg | 5 mg | 12 weeks | — |
| Effects of a food supplement containing phosphatidylserine on cognitive function in Chinese older adults with mild cognitive impairment: A randomized double-blind, placebo-controlled trial 2025 · intervention group · Chinese adults with mild cognitive impairment; mean age 67.95 years; 70 male and 120 female | 960 mcg | 180 mcg | 1 year | 95 |
| Efficacy of multivitamin supplementation containing vitamins B6 and B12 and folic acid as adjunctive treatment with a cholinesterase inhibitor in Alzheimer's disease: a 26-week, randomized, double-blind, placebo-controlled study in Taiwanese patients 2007 · mecobalamin (B12) + multivitamin supplement · Taiwanese men and women aged over 50 with mild to moderate Alzheimer's disease and normal folic acid and vitamin B12 concentrations | 5 mg | 1 mg | 26 weeks | 45 |
| L-Arginine and B vitamins improve endothelial function in subjects with mild to moderate blood pressure elevation 2018 · Nutritional intervention group · Men and postmenopausal women aged 40–65 with slightly to moderately elevated blood pressure | 3 mg | 400 mcg | 26 weeks | 40 |
| L-Arginine and B vitamins improve endothelial function in subjects with mild to moderate blood pressure elevation 2018 · Placebo group receiving open-label TAP in follow-up · Men and postmenopausal women aged 40–65 with slightly to moderately elevated blood pressure | 3 mg | 400 mcg | 13 weeks | 40 |
| Improving neuropathy scores in type 2 diabetic patients using micronutrients supplementation 2011 · Group MVB · Patients with type 2 diabetes | 10 mg | 1 mg | 120 days | — |
| Three-month B vitamin supplementation in pre-school children affects folate status and homocysteine, but not cognitive performance 2014 · B vitamin supplementation group · Healthy preschool children selected for low urinary folate-status ranking | 730 mcg | 220 mcg | 90 days | — |
| Low-dose B vitamins supplementation ameliorates cardiovascular risk: a double-blind randomized controlled trial in healthy Chinese elderly 2015 · treatment group · Healthy adults aged 60–74 years | 2 mg | 400 mcg | 1 year | — |
| Lowering homocysteine with B vitamins has no effect on blood pressure in older adults 2007 · Vitamins group · Healthy adults aged 65 years or older with homocysteine concentrations of at least 13 micromol/L | 10 mg | 1 mg | 2 years | — |
| A 2-Year Randomized Controlled Trial With Low-Dose B-Vitamin Supplementation Shows Benefits on Bone Mineral Density in Adults With Lower B12 Status 2022 · B-vitamin treatment · Community-dwelling adults aged 50 years or older; men and women; no specific diagnosed condition, and not currently taking B-vitamin supplements at screening | 10 mg | 200 mcg | 2 years | 103 |
| Aged garlic extract supplemented with B vitamins, folic acid and L-arginine retards the progression of subclinical atherosclerosis: a randomized clinical trial 2009 · AGE+S · Intermediate-risk adults, mean age 60 ± 9 years; 79% male | 12.5 mg | 300 mcg | 1 year | — |
| Effect of Combined Treatment With Folic Acid, Vitamin B(6), and Vitamin B(12) on Plasma Biomarkers of Inflammation and Endothelial Dysfunction in Women 2018 · Folic Acid/B6/B12 · Adult women at increased cardiovascular risk, with pre-existing cardiovascular disease or at least three coronary risk factors | 50 mg | 2.5 mg | 2665 days | 150 |
| Homocysteine-lowering treatment with folic acid, cobalamin, and pyridoxine does not reduce blood markers of inflammation, endothelial dysfunction, or hypercoagulability in patients with previous transient ischemic attack or stroke: a randomized substudy of the VITATOPS trial 2005 · vitamin therapy · Patients with recent transient ischemic attack or stroke; age and sex not reported | 25 mg | 2 mg | 26 weeks | — |
| Sustained homocysteine-lowering effect over time of folic acid-based multivitamin therapy in stroke patients despite increasing folate status in the population 2005 · active VITATOPS medication · Patients with stroke or transient ischemic attack | 25 mg | 2 mg | 26 weeks | — |
| Decrease of carotid intima-media thickness in patients at risk to cerebral ischemia after supplementation with folic acid, Vitamins B6 and B12 2005 · treatment group · Adults aged 60 ± 8 years with carotid intima-media thickness ≥1 mm and at risk of cerebral ischemia | 25 mg | 2.5 mg | 1 year | — |
| Effect of long-term homocysteine reduction with B vitamins on arterial wall inflammation assessed by fluorodeoxyglucose positron emission tomography: a randomised double-blind, placebo-controlled trial 2009 · B-vitamin therapy · Adults with a history of ischemic stroke | 25 mg | 2 mg | 1461 days | — |
| Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial 2010 · B-vitamin group · People with type 1 or type 2 diabetes and a clinical diagnosis of diabetic nephropathy | 25 mg | 2.5 mg | 3 years | — |
| Folic acid causes higher prevalence of detectable unmetabolized folic acid in serum than B-complex: a randomized trial 2016 · B-complex · Elderly people | 8 mg | 400 mcg | 23 days | 27 |
| Distribution of plasma folate forms in hemodialysis patients receiving high daily doses of L-folinic or folic acid 2002 · Folic acid group · Adults with chronic stable hemodialysis and hyperhomocysteinemia | 50 mg | 15 mg | 12 weeks | 24 |
| Holo-transcobalamin is an early marker of changes in cobalamin homeostasis. A randomized placebo-controlled study 2002 · Vitamin B(12), folic acid, and vitamin B(6) · Patients aged 38–80 years undergoing coronary angiography | 40 mg | 800 mcg | 12 weeks | — |
| Plasma vitamin B6 vitamers before and after oral vitamin B6 treatment: a randomized placebo-controlled study 2003 · Group A · Patients aged 38–80 years undergoing coronary angiography | 40 mg | 800 mcg | 12 weeks | — |
| Concentrations of unmetabolized folic acid and primary folate forms in plasma after folic acid treatment in older adults 2011 · folic acid treatment group · Older adults, median age 82 years; sex and health condition not specified | 40 mg | 5 mg | 3 weeks | — |
| One year B-vitamins increases serum and whole blood folate forms and lowers plasma homocysteine in older Germans 2015 · B-vitamin supplementation · Older German adults, mean age 67 years | 50 mg | 500 mcg | 1 year | — |
| Maternal B-vitamin and vitamin D status before, during, and after pregnancy and the influence of supplementation preconception and during pregnancy: Prespecified secondary analysis of the NiPPeR double-blind randomized controlled trial 2023 · intervention · Women planning pregnancy; generally healthy, recruited before conception | 2.6 mg | 400 mcg | — | 870 |
| Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease 2015 · Active group (RCT1, RCT2 and RCT3) · Men and women aged 50 years or older with mild or mild-to-moderate Alzheimer's disease; RCT3 participants were on stable approved Alzheimer's medication, while RCT1 and RCT2 participants were drug-free for Alzheimer's medication. | 1 mg | 400 mcg | 24 weeks | 501 |
| Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease 2015 · Active product during open-label extension (OLE) · Men and women aged 50 years or older with mild Alzheimer's disease who completed RCT2. | 1 mg | 400 mcg | 24 weeks | 201 |
| Lowering plasma homocysteine concentrations of older men and women with folate, vitamin B-12, and vitamin B-6 does not affect the proportion of (n-3) long chain polyunsaturated fatty acids in plasma phosphatidylcholine 2008 · vitamin group · Men and women aged 65 years or older with plasma homocysteine concentrations of at least 13 micromol/L | 10 mg | 1 mg | 2 years | 127 |
| Paraoxonase 1, B Vitamins Supplementation, and Mild Cognitive Impairment 2021 · B-vitamin group · Men and women, mean age 77.6 years, with mild cognitive impairment | 20 mg | 800 mcg | 2 years | 95 |
| Brain atrophy in cognitively impaired elderly: the importance of long-chain ω-3 fatty acids and B vitamin status in a randomized controlled trial 2015 · high-dose B vitamin supplementation · Adults aged 70 years or older with mild cognitive impairment | 20 mg | 800 mcg | 2 years | 85 |
| The effect of long-term homocysteine-lowering on carotid intima-media thickness and flow-mediated vasodilation in stroke patients: a randomized controlled trial and meta-analysis 2008 · Vitamins · People with a history of stroke or transient ischemic attack; age range and sex not restricted | 25 mg | 2 mg | 4 years | 83 |
| Homocysteine-lowering treatment with folic acid plus vitamin B6 lowers urinary albumin excretion but not plasma markers of endothelial function or C-reactive protein: further analysis of secondary end-points of a randomized clinical trial 2003 · Folic acid plus vitamin B6 treatment · Healthy adults who were siblings of patients with premature atherosclerotic disease | 250 mg | 5 mg | 2 years | 78 |
| Effect of homocysteine-lowering treatment with folic acid plus vitamin B on cerebrovascular atherosclerosis and white matter abnormalities as determined by MRA and MRI: a placebo-controlled, randomized trial 2004 · vitamin-treated group · Healthy siblings of patients with premature atherosclerotic disease; mean age 46.0 years; sex not specified | 250 mg | 5 mg | 2 years | 78 |
| Supplementation with antioxidant micronutrients in pregnant women with obesity: a randomized controlled trial 2024 · Intervention group · Pregnant women with obesity (BMI ≥30 kg/m²) | 18 mg | 800 mcg | — | 64 |
| Homocysteine thiolactone contributes to the prognostic value of fibrin clot structure/function in coronary artery disease 2022 · Folic acid + vitamins B12, B6 · Adults with suspected coronary artery disease undergoing angiography for stable angina; mean age 61.2 years, 71.5% male | 40 mg | 800 mcg | 1387 days | 52 |
| Betaine supplementation decreases post-methionine hyperhomocysteinemia in chronic renal failure 2002 · Folic acid and pyridoxine without glycine betaine · Patients with chronic renal failure who were folate and pyridoxine replete | 50 mg | 5 mg | 90 days | 36 |
| Betaine supplementation decreases post-methionine hyperhomocysteinemia in chronic renal failure 2002 · Folic acid, pyridoxine, and glycine betaine · Patients with chronic renal failure who were folate and pyridoxine replete | 50 mg | 5 mg | 90 days | 36 |
| Randomized trial of FX high flux vs standard high flux dialysis for homocysteine clearance 2005 · All patients receiving vitamin therapy · Haemodialysis patients with end-stage renal disease; age and sex not reported | 25 mg | 5 mg | 24 weeks | 35 |
| [Efficacy and safety of two vitamin supplement regimens on homocysteine levels in hemodialysis patients. Prospective, randomized clinical trial] 2005 · Supraphysiological daily-dose regimen · Adults with stable maintenance hemodialysis (mean age 68 years; 48% male) | 100 mg | 15 mg | 1 year | 33 |
| A Randomized Pilot Trial to Evaluate the Bioavailability of Natural versus Synthetic Vitamin B Complexes in Healthy Humans and Their Effects on Homocysteine, Oxidative Stress, and Antioxidant Levels 2019 · Natural vitamin B complex (group N) · Healthy adults; age range and sex not specified | 3.38 mg | 690 mcg | 6 weeks | 30 |
| A Randomized Pilot Trial to Evaluate the Bioavailability of Natural versus Synthetic Vitamin B Complexes in Healthy Humans and Their Effects on Homocysteine, Oxidative Stress, and Antioxidant Levels 2019 · Synthetic vitamin B complex (group S) · Healthy adults; age range and sex not specified | 3.38 mg | 690 mcg | 6 weeks | 30 |
| Plasma homocysteine and markers for oxidative stress and inflammation in patients with coronary artery disease--a prospective randomized study of vitamin supplementation 2005 · open therapy with vitamins · Adults with ischemic heart disease and plasma homocysteine at least 15.0 micromol/L | 40 mg | 5 mg | 90 days | 29 |
| The impact of folate status and folic acid supplementation on the micronucleus frequency in human erythrocytes 2006 · folic acid, vitamin B12 and vitamin B6 supplementation group · Both-sex participants without folate deficiency; age not reported | 4 mg | 800 mcg | 7 days | 29 |
| Vitamin supplementation reduces the progression of atherosclerosis in hyperhomocysteinemic renal-transplant recipients 2003 · group A · Adults with hyperhomocysteinemia who were stable renal-transplant recipients | 50 mg | 5 mg | 26 weeks | 28 |
| [Efficacy and safety of two vitamin supplement regimens on homocysteine levels in hemodialysis patients. Prospective, randomized clinical trial] 2005 · Daily renal multivitamin regimen · Adults with stable maintenance hemodialysis (mean age 68 years; 48% male) | 10 mg | 5 mg | 1 year | 27 |
| Comparative study of response to treatment with supraphysiologic doses of B-vitamins in hyperhomocysteinemic hemodialysis patients 2004 · Group A · Hemodialysis patients with hyperhomocysteinemia; age and sex not reported | 25 mg | 15 mg | — | 26 |
| Controlled comparison of L-5-methyltetrahydrofolate versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients 2000 · FA group · Adults with chronic, stable hyperhomocysteinemia receiving hemodialysis | 50 mg | 15 mg | 12 weeks | 25 |
| Treatment of hyperhomocysteinemia in hemodialysis patients and renal transplant recipients 2001 · Folic acid group · Adults with chronic, stable hyperhomocysteinemia receiving maintenance hemodialysis | 50 mg | 15 mg | 12 weeks | 25 |
| Rapid communication: L-folinic acid versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients 2001 · Folic acid group · Adults with chronic, stable hyperhomocysteinemia receiving hemodialysis | 50 mg | 15 mg | 12 weeks | 24 |
| Comparative study of response to treatment with supraphysiologic doses of B-vitamins in hyperhomocysteinemic hemodialysis patients 2004 · Group B · Hemodialysis patients with hyperhomocysteinemia; age and sex not reported | 100 mg | 15 mg | — | 24 |
| Antioxidant supplementation with or without B-group vitamins after acute ischemic stroke: a randomized controlled trial 2006 · B-group vitamins · Acute ischemic stroke patients treated within 12 hours of symptom onset | 50 mg | 5 mg | 2 weeks | 24 |
| Antioxidant supplementation with or without B-group vitamins after acute ischemic stroke: a randomized controlled trial 2006 · Antioxidant vitamins plus B-group vitamins · Acute ischemic stroke patients treated within 12 hours of symptom onset | 50 mg | 5 mg | 2 weeks | 24 |
| Enhanced reduction of fasting total homocysteine levels with supraphysiological versus standard multivitamin dose folic acid supplementation in renal transplant recipients 1999 · group 1 · Chronic, stable renal transplant recipients; age and sex not stated | 50 mg | 2.4 mg | 12 weeks | 20 |
| Enhanced reduction of fasting total homocysteine levels with supraphysiological versus standard multivitamin dose folic acid supplementation in renal transplant recipients 1999 · group 2 · Chronic, stable renal transplant recipients; age and sex not stated | 50 mg | 400 mcg | 12 weeks | 20 |
| Vitamin B(6) supplementation improves pro-inflammatory responses in patients with rheumatoid arthritis 2010 · vitamin B(6) · Patients with rheumatoid arthritis | 100 mg | 5 mg | 12 weeks | 20 |
| Hyperhomocysteinemia and endothelial function in young subjects: effects of vitamin supplementation 2002 · vitamin supplementation · Male volunteers aged 40 years or younger; nine matched pairs received vitamins, including hyperhomocysteinemic and normohomocysteinemic subjects | 2 mg | 600 mcg | 8 weeks | 18 |
| [Treatment of hyperhomocysteinemia and endothelial dysfunction in renal-transplant recipients with vitamin B] 2005 · vitamin treatment (group A) · Stable hyperhomocysteinemic renal-transplant recipients | 50 mg | 5 mg | 26 weeks | 18 |
| Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial 2020 · DHA treatment arm · Cognitively unimpaired men and women aged 55 years and older with a first-degree family history of dementia | 100 mg | 800 mcg | 26 weeks | 18 |
| Treatment of hyperhomocysteinemia in hemodialysis patients and renal transplant recipients 2001 · Renal transplant recipients · Renal transplant recipients with hyperhomocysteinemia | 50 mg | 2.4 mg | 12 weeks | 10 |
| Efficacy of methylcobalamin on lowering total homocysteine plasma concentrations in haemodialysis patients receiving high-dose folic acid supplementation 2002 · group III · Haemodialysis patients with chronic renal failure and hyperhomocysteinaemia | 60 mg | 15 mg | 3 weeks | 7 |
| Treatment of hyperhomocysteinemia in renal transplant recipients. A randomized, placebo-controlled trial 1997 · vitamin B6, folic acid, and vitamin B12 · Clinically stable renal transplant recipients | 50 mg | 5 mg | — | 7 |
| Treatment of hyperhomocysteinemia in hemodialysis patients and renal transplant recipients 2001 · Hemodialysis patients receiving folic acid · Hemodialysis patients with hyperhomocysteinemia and baseline total homocysteine comparable to the renal transplant recipients | 50 mg | 15 mg | 12 weeks | — |
| Low-dose vitamin B-6 effectively lowers fasting plasma homocysteine in healthy elderly persons who are folate and riboflavin replete 2001 · Vitamin B-6 supplementation group · Healthy adults aged 63–80 years; folate- and riboflavin-replete, with no vitamin B-12 deficiency | 1.6 mg | 400 mcg | 12 weeks | — |
| Vitamin supplementation can markedly reduce the homocysteine elevation induced by fenofibrate 2001 · fenofibrate plus vitamins · men with hyperlipidemia | 5 mg | 650 mcg | 6 weeks | — |
| Effect of homocysteine reduction by B-vitamin supplementation on markers of clotting activation 2002 · high-dose B-vitamin supplements · Healthy volunteers with homocysteine >16 μmol/L or ≤16 μmol/L | 50 mg | 5 mg | 8 weeks | — |
| Reduction of plasma homocysteine and serum methylmalonate concentrations in apparently healthy elderly subjects after treatment with folic acid, vitamin B12 and vitamin B6: a randomised trial 2003 · B-vitamin treatment · Community-dwelling apparently healthy adults aged 70–93 years; median age 76 years | 3 mg | 800 mcg | 120 days | — |
| Mineral water fortified with folic acid, vitamins B6, B12, D and calcium improves folate status and decreases plasma homocysteine concentration in men and women 2004 · Fortified mineral water · Free-living men and women without folate deficiency or elevated homocysteine | 1 mg | 563 mcg | 8 weeks | — |
| Breakfast cereal fortified with folic acid, vitamin B-6, and vitamin B-12 increases vitamin concentrations and reduces homocysteine concentrations: a randomized trial 2004 · Fortified cereal group · Volunteers aged 50–85 years without the listed medical conditions who did not regularly use multiple or B-vitamin supplements or highly fortified breakfast cereal | 1.8 mg | 440 mcg | 12 weeks | — |
| The effect of homocysteine reduction by B-vitamin supplementation on markers of endothelial dysfunction 2004 · B-vitamins · Healthy volunteers, including hyperhomocysteinemic and normohomocysteinemic participants | 50 mg | 5 mg | 8 weeks | — |
| Efficacy of B vitamins in lowering homocysteine in older men: maximal effects for those with B12 deficiency and hyperhomocysteinemia 2006 · Vitamin group · Community-dwelling men aged 75 years or older | 25 mg | 2 mg | 2 years | — |
| No effect of B vitamins on ADMA levels in patients at increased cardiovascular risk 2006 · Study I: B vitamins · Siblings of patients with clinical atherosclerotic disease and postmethionine hyperhomocysteinaemia; ages and sex not stated | 250 mg | 5 mg | 1 year | — |
| Effect of short-term folate and vitamin B supplementation on blood homocysteine level and carotid artery wall thickness in chronic hemodialysis patients 2006 · Treatment group · Chronic hemodialysis patients with hyperhomocysteinemia; age and sex not specified | 50 mg | 15 mg | 26 weeks | — |
| Effect of fortified spread on homocysteine concentration in apparently healthy volunteers 2007 · spread 1 · Apparently healthy adult volunteers; 50% male; age range not reported | 1 mg | 200 mcg | 6 weeks | — |
| Effect of fortified spread on homocysteine concentration in apparently healthy volunteers 2007 · spread 2 · Apparently healthy adult volunteers; 50% male; age range not reported | 1 mg | 400 mcg | 6 weeks | — |
| Homocysteine-lowering therapy does not affect inflammatory markers of atherosclerosis in patients with stable coronary artery disease 2007 · A: folic acid/vitamin B12/vitamin B6 · Adults aged 38–80 with suspected coronary artery disease | 40 mg | 800 mcg | 26 weeks | — |
| Treatment of hyperhomocysteinemia and endothelial dysfunction in renal transplant recipients with B vitamins in the Chinese population 2008 · folate treatment · Chinese renal transplant recipients with hyperhomocysteinemia; age and sex not reported | 50 mg | 5 mg | 26 weeks | — |
| Effect of homocysteine-lowering therapy on arterial elasticity and metabolic parameters in metformin-treated diabetic patients 2008 · group 1 · Adults with diabetes treated with high-dose metformin | 10 mg | 1 mg | 120 days | — |
| Serum biomarkers for atrophic gastritis and antibodies against Helicobacter pylori in the elderly: Implications for vitamin B12, folic acid and iron status and response to oral vitamin therapy 2008 · oral vitamin treatment · Community-dwelling adults, mean age 76 years | 3 mg | 800 mcg | 120 days | — |
| The effects of vitamin supplementation and MTHFR (C677T) genotype on homocysteine-lowering and migraine disability 2009 · vitamin supplementation · patients diagnosed with migraine with aura; age and sex not reported | 25 mg | 2 mg | 26 weeks | — |
| Homocysteine-lowering vitamins do not lower plasma S-adenosylhomocysteine in older people with elevated homocysteine concentrations 2010 · vitamins group · Healthy adults aged 65 years or older with elevated homocysteine (>13 micromol/l) | 10 mg | 1 mg | 2 years | — |
| Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment 2013 · B-vitamin treatment · Elderly adults with mild cognitive impairment and increased dementia risk | 20 mg | 800 mcg | 2 years | — |
| The association between progression of atherosclerosis and the methylated amino acids asymmetric dimethylarginine and trimethyllysine 2013 · Folic acid plus vitamin B12 plus vitamin B6 · Adults with suspected or established coronary artery disease who underwent coronary angiography; median age 60 years | 40 mg | 800 mcg | 316 days | — |
| Urinary excretion of homocysteine thiolactone and the risk of acute myocardial infarction in coronary artery disease patients: the WENBIT trial 2019 · folic acid + vitamin B12 + vitamin B6 · Adults with suspected coronary artery disease who underwent coronary angiography; mean age about 61 years, 69.8% male | 40 mg | 800 mcg | 165 weeks | — |
| Vitamin requirements for the treatment of hyperhomocysteinemia in humans 1994 · combination of folic acid, vitamin B-12 and vitamin B-6 · men with hyperhomocysteinemia | 10 mg | 650 mcg | 6 weeks | — |
| Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia 1993 · daily vitamin supplement · Apparently healthy men with moderate hyperhomocysteinemia | 10 mg | 1 mg | 6 weeks | — |
| Vitamin supplementation reduces blood homocysteine levels: a controlled trial in patients with venous thrombosis and healthy volunteers 1998 · high-dose multivitamin supplements · Patients with a history of recurrent venous thrombosis and hyperhomocysteinemic healthy volunteers | 50 mg | 5 mg | — | — |
| Nutraceutical approaches to homocysteine lowering in hypertensive subjects at low cardiovascular risk: a multicenter, randomized clinical trial 2016 · Normocis 400® group · Adults with stage 1 essential hypertension and hyper-homocysteinemia (HCys ≥15 μmol/L), without a history of cardiovascular or cerebrovascular disease; mean age 62.8 years, 63.5% male | 3 mg | 400 mcg | 60 days | 52 |
| Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD 2009 · Treatment group · Adults with stage 2 to 4 chronic kidney disease and creatinine clearance of 15 to 70 mL/min/1.73 m² | 100 mg | 5 mg | 2 years | 47 |
| Effects of low-dose B vitamins plus betaine supplementation on lowering homocysteine concentrations among Chinese adults with hyperhomocysteinemia: a randomized, double-blind, controlled preliminary clinical trial 2023 · supplement group · Chinese adults aged 18–65 with hyperhomocysteinemia (blood homocysteine 15–100 μmol/L) | 8 mg | 400 mcg | 12 weeks | 44 |
| Plasma trimethylamine-N-oxide following supplementation with vitamin D or D plus B vitamins 2017 · vitamin D + B arm · Participants; age, sex, and health condition not specified | 50 mg | 500 mcg | 1 year | 25 |
| High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients 1996 · Supraphysiologic-dose B-vitamin supplementation · Hyperhomocysteinemic dialysis patients | 100 mg | 15 mg | 8 weeks | 15 |
| Total homocysteine lowering treatment among coronary artery disease patients in the era of folic acid-fortified cereal grain flour 2002 · Folic acid, riboflavin, and vitamin B12 with vitamin B6 · Adults with stable coronary artery disease; mean age 60.1 years; 29.8% women | 50 mg | 2.5 mg | 12 weeks | — |
| Folate therapy and in-stent restenosis after coronary stenting 2004 · folate group · Patients who had undergone successful coronary stenting | 48 mg | 1.2 mg | 26 weeks | — |
| Changes in basal and postmethionine load concentrations of total homocysteine and cystathionine after B vitamin intervention 2004 · group A · Patients with suspected coronary artery disease; age and sex not stated | 40 mg | 5.8 mg | 90 days | — |
| One year B and D vitamins supplementation improves metabolic bone markers 2013 · group A · Healthy adults older than 54 years | 50 mg | 500 mcg | 1 year | — |
| Co-administration of methyl donors along with guanidinoacetic acid reduces the incidence of hyperhomocysteinaemia compared with guanidinoacetic acid administration alone 2013 · GAA with methyl donors group · Healthy male and female volunteers | 10 mg | 600 mcg | 8 weeks | — |
| Effects of mixed dietary supplements on total plasma homocysteine concentrations (tHcy): a randomized, double-blind, placebo-controlled trial 2012 · supplement group · hospitalized, acutely ill older patients recovering from acute illness; sex and age range not stated | 1.4 mg | 200 mcg | 6 weeks | — |
| One-carbon metabolites and telomere length in a prospective and randomized study of B- and/or D-vitamin supplementation 2017 · group A · Adults older than 54 years; no specific condition stated | 50 mg | 500 mcg | 1 year | — |
| Betaine as a determinant of postmethionine load total plasma homocysteine before and after B-vitamin supplementation 2004 · folic acid, vitamin B12, and vitamin B6 group · Patients undergoing coronary angiography | 40 mg | 800 mcg | 1 year | — |